Welcome to our dedicated page for Galectin Therapeutics SEC filings (Ticker: GALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotechnology filing packed with enzyme pathways and Phase 2 endpoints can feel like decoding a new language. Galectin Therapeutics’ documents add another layer of complexity by detailing how carbohydrate polymers blunt galectin-3 to slow liver fibrosis. If you have ever searched for “Galectin Therapeutics SEC filings explained simply” or wondered where the “Galectin Therapeutics quarterly earnings report 10-Q filing” hides cash-burn clues, you know the challenge.
Stock Titan turns that challenge into clarity. Our AI instantly extracts trial timelines, financing terms, and risk factors from every 10-K and 10-Q, giving you a “Galectin Therapeutics annual report 10-K simplified” in minutes. Real-time alerts flag each “Galectin Therapeutics 8-K material events explained,” while concise dashboards track “Galectin Therapeutics insider trading Form 4 transactions.” Need to monitor management confidence? We surface every “Galectin Therapeutics executive stock transactions Form 4” as soon as they hit EDGAR, along with context that links trades to upcoming liver-fibrosis data releases.
Whether you are comparing R&D spend trends, scanning the “Galectin Therapeutics proxy statement executive compensation,” or seeking “Galectin Therapeutics earnings report filing analysis,” our platform keeps biotech nuance front and center. AI-powered summaries translate statistical jargon into everyday language, highlight non-cash charges, and point to footnotes on trial enrollment hurdles—so understanding Galectin Therapeutics SEC documents with AI becomes part of your routine, not an all-night project. All filings, all forms, always up to date, with “Galectin Therapeutics Form 4 insider transactions real-time” monitoring just a click away.
Galectin Therapeutics Inc. reported the results of its 2025 Annual Meeting of Stockholders held on December 3, 2025. Stockholders elected all nominated directors to serve until the next annual meeting or until their successors are elected and qualified, with each nominee receiving more votes for than withheld.
Stockholders approved a non-binding advisory resolution on executive compensation, with 25,260,489 votes for, 639,415 against and 310,420 abstentions, alongside 19,513,532 broker non-votes. In a separate advisory vote on how often to hold future say-on-pay votes, 22,075,944 votes favored a three-year frequency, and the Board determined that advisory votes on named executive officer compensation will be held every three years. Stockholders also ratified the selection of Cherry Bekaert LLP as the company’s independent registered public accounting firm for the year ending December 31, 2025, with 45,458,024 votes for, 142,268 against and 123,564 abstentions.
Galectin Therapeutics Inc. (GALT) reported insider transactions by its President and CEO, who is also a director. On November 17, 2025, the executive exercised stock options to buy 15,680 shares of common stock at $2.39 per share and sold the same number of shares at a weighted average price of $6.0359. On November 18, 2025, the executive similarly exercised options for 6,783 shares at $2.39 and sold those shares at a weighted average price of $6.1511. After these transactions, the executive directly owned 832,592 common shares and indirectly held 2,000 shares as custodian for a minor child. The filing notes that the trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on April 17, 2025, and that the options exercised had vested fully on December 14, 2018.
Galectin Therapeutics Inc. (GALT) CFO Jack W. Callicutt reported multiple option exercises and related stock sales. On November 17 and 18, 2025, he exercised several stock options to buy common shares at exercise prices of
Sale prices were reported as weighted averages of about
Galectin Therapeutics Inc. filed an 8-K stating it furnished a press release with results of operations and financial condition for the nine months ended September 30, 2025, along with a business update. The information under Item 2.02 is furnished, not filed, and the press release is attached as Exhibit 99.1 dated November 14, 2025.
Galectin Therapeutics (GALT) filed its Q3 2025 10‑Q, reporting a net loss of
Cash and equivalents were
Total assets were
Galectin Therapeutics (GALT) CEO and Director reported a Rule 10b5-1 trade. On 11/10/2025, he exercised 1,867 stock options at $2.39 and sold 1,867 common shares at a weighted average price of $6.0269 (sales ranged from $6.00 to $6.12). The exercised options were granted on 12/14/2018 and vested 100%.
Following the transactions, he beneficially owns 832,592 shares directly, plus 2,000 shares indirectly as custodian for a minor child. He also reports 22,363 derivative securities (options) beneficially owned.
Galectin Therapeutics (GALT) CFO Jack W. Callicutt reported option exercises and same‑day sales on 11/10/2025 under a Rule 10b5‑1 plan adopted on April 17, 2025. He exercised stock options for 5,291 shares (strike prices: $1.11, $1.23, and $1.98) and sold the same number of shares in open‑market transactions.
Sales were executed at weighted average prices of $6.022, $6.0266, and $6.0298, with individual trades ranging from $6.00 to $6.14. Following these transactions, he directly owned 7,614 shares of common stock.
Galectin Therapeutics (GALT) reported that it presented results from its NAVIGATE trial at the AASLD 2025 Annual Meeting and posted an updated Corporate Presentation. The company also issued a press release; both materials were provided as Exhibits 99.1 and 99.2.
The materials were furnished under Item 7.01 of a Form 8-K and are not deemed filed under the Exchange Act. The disclosures include forward-looking statements subject to the cautionary notes in the exhibits and other SEC reports.
Galectin Therapeutics (GALT) reported an insider transaction by its President and CEO, who is also a Director. On 11/05/2025, the executive exercised 200 stock options at $2.39 and sold 200 common shares at $6.00, executed under a Rule 10b5-1 plan.
Following these transactions, the executive reported 832,592 common shares held directly. An additional 2,000 shares are held indirectly as custodian for a minor child under the Uniform Transfers to Minors Act, with beneficial ownership disclaimed. The exercised options were from a grant that vested 100% on 12/14/2018 and expire on 12/14/2027, with 24,230 derivative securities reported as beneficially owned after the transaction.
Galectin Therapeutics (GALT) Form 4: CFO Jack W. Callicutt exercised stock options for 600 shares and sold 600 shares on 11/05/2025 under a Rule 10b5-1 plan. Exercises occurred at $1.98, $1.11, and $1.72 per share, with sales at $6. Following these transactions, he held 7,614 shares directly.
FAQ
What is the current stock price of Galectin Therapeutics (GALT)?
What is the market cap of Galectin Therapeutics (GALT)?
